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Abstract
Peanut allergy, the most persistent and deadly of the food allergies, has
become more prevalent worldwide in recent decades. Numerous explanations
have been offered for the rise in peanut allergy, which has been more
pronounced in Western, industrialized nations. In infants who are at increased
risk of peanut allergy, new evidence indicates that early introduction of peanuts
can help prevent allergy development. This counterintuitive finding directly
contradicts the previously established practice of peanut avoidance for
high-risk infants but is supported by clinical and basic science evidence. Here,
we review the literature contributing to our evolving understanding of nut
allergy, emphasizing the translation of this work to clinical practice.
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Introduction
The global impact of food allergy has increased in the past few 
decades, and industrialized countries appear to be dispropor-
tionately affected. Food allergy prevalence is marked in the 
US, where incidence is as high as 10% in 1-year-olds1 and 
estimates of economic impact are as high as $25 billion per 
year2. Anaphylaxis, which is caused by IgE-mediated degranula-
tion of mast cells and basophils, is the most serious form of food 
hypersensitivity and may result in hypotension, shock, and 
bronchospasm. Admissions for food anaphylaxis in children 
have doubled in the last decade, and US emergency department 
visits related to food allergy have also significantly increased3. 
Death caused by food-induced anaphylaxis is extremely rare4, 
but peanuts and tree nuts are believed to cause a disproportionate 
share of these deaths, more than 90% by some estimates4, 
and as many as 18% to 40% of all food-induced anaphylactic 
reactions are estimated to be caused by tree nuts5,6. The prev-
alence of both tree nut and peanut allergy appears to be 
increasing, at least in the pediatric population; a survey of 
5,300 households found that the prevalence of tree nut or 
peanut allergy rose from 1.2% in 2002 to 2.1% in 20087. Walnuts, 
hazelnuts, cashews, and almonds are the tree nuts that most 
likely cause allergic reactions. For both peanuts and many 
tree nuts, the quantity required to trigger an allergic reaction 
(50% of the maximum response, or ED50) is very low compared 
with other major food allergens8.
Given the ubiquity of nuts in Western diets and the rising 
prevalence of nut allergy, it is unsurprising that stories about 
fatal nut-related anaphylaxis have gained traction in the lay press. 
News articles, such as those written about a Canadian woman 
who died after a peanut-laced kiss, further heighten public anxiety 
about nut allergy9. Many elementary schools in the US have 
responded to increased concerns about nuts by instituting 
“nut-free zones” and policies. Blogs and websites like “No Nuts 
Moms Group” promoting nut-free policies have proliferated. 
Nut allergy is associated with significant psychological 
burden10 and has a negative impact on quality of life11. Patients 
with nut allergy are subject to increased stress and anxiety, as 
ordinary activities such as grocery shopping or eating at a 
restaurant can provoke fear10.
Allergic potential of peanuts and tree nuts
Peanuts (Arachis hypogea) and tree nuts are seeds and, as 
such, contain numerous energy storage proteins. Botanically, 
neither peanuts nor many tree nuts are true nuts. Peanuts are 
legumes, a group that also includes peas, beans, chickpeas, 
soybeans, alfalfa, and clover. Hazelnuts and chestnuts are true 
nuts, composed of an edible seed surrounded by a hard shell, 
which is surrounded by a woody protective layer. Most other tree 
nuts are drupe seeds. Drupes, also known as stone fruits, com-
prise a category of botanical fruit that includes the culinary fruits 
apricots, peaches, mangos, and nectarines. The seeds of these 
fruits are housed in a hardened exocarp or “pit”, which in turn 
is typically surrounded by juicy flesh and thin skin. Pecans, 
walnuts, almonds, cashews, and pistachios are all considered 
drupe seeds rather than nuts.
At least three broad categories of seed storage protein have 
been identified as potentially being important in food allergy: 
2S albumins, vicilins (7S globulins), and legumins (11S globu-
lins). In peanuts, Ara h 1 is a vicilin, Ara h 2 is a 2S albumin, and 
Ara h 3 is a legumin; of these, Ara h 2 is likely responsible for 
most anaphylactic reactions12,13. Patients with peanut allergy may 
have a positive skin prick test (SPT) or serum test to tree nut extract 
as the result of cross-sensitization, in which epitope similarity 
allows a single immunoglobulin to bind to different proteins14.
One factor contributing to the allergenicity of peanuts and tree 
nuts is their ability to activate the innate immune system. For 
instance, group 2 innate lymphoid cells are increased in 
peanut-allergic patients compared with non-atopic controls15. 
Furthermore, peanuts have been shown to contribute to shock in 
mice by stimulating the production of the complement compo-
nent C3a, independently of any adaptive immune response to 
peanut proteins16. Innate immune cells, including dendritic cells, 
macrophages, and natural killer cells, express pattern recogni-
tion receptors (PRRs), including Toll-like receptors, Nod-like 
receptors, and Rig-like receptors, which often bind to substances 
that are present in injury or infection. Substances that enhance 
the innate immune response to an antigen, particularly through 
the stimulation of PRRs, are referred to as adjuvants. Examples 
of well-characterized adjuvants are lipopolysaccharide (LPS), 
which is produced by Gram-negative bacteria, and beta glucan, 
which is produced by fungi. There is some evidence that highly 
allergenic drupe seeds and legumes may promote innate immune 
activation in a way that less-allergenic legumes do not. One 
experiment showed that peanut extract injected into a mouse 
foot led to increased cell number and cytokine production in the 
ipsilateral popliteal lymph node17. In another study, peanut 
exposure to abraded mouse skin also increased innate cytokine 
peanut-specific IgE/IgG1 production, even without the addition 
of an exogenous adjuvant18. In the same study, cashew exposure 
without adjuvant also led to the generation of cashew-specific 
IgE/IgG118. However, mice exposed to an extract of green 
bean (a less-allergenic legume) did not develop a similar IgE 
response unless cholera toxin, an established exogenous 
adjuvant, was added to the solution18.
Use of component-resolved diagnostics for peanut 
and tree nut allergies
Specific IgE immunoassays (sIgE) (described above) may yield 
a positive result even when a patient does not have a clinically 
significant allergy to the allergen in question. The sIgE 
technique uses peanut or tree nut extract. However, not all 
peanut and tree nut proteins are equally allergenic, and the 
presence of IgE to some proteins is more strongly associated 
with severe allergy than others. With peanuts, patients with sIgE 
to the “anaphylactogenic” protein Ara h 2 are more likely to 
develop severe, systemic reactions than patients with Ara h 8, 
as Ara h 8 is homologous to Bet v 1 and other birch pollen 
allergens and therefore associated with the milder oral allergy 
syndrome19. Component-resolved diagnostics (CRD) use recom-
binant protein immunoassays rather than extracts to determine 
which specific proteins patient antibodies are reactive to. In a 
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patient with a positive sIgE to peanut, CRD can elucidate which 
of the Ara proteins the patient’s antibodies are reactive to and 
therefore can predict the clinical severity of the patient’s 
allergy. Early studies indicate that CRD is a promising tool for 
making such predictions20. A recent experiment involving the use 
of CRD in 108 patients with peanut allergy suggested that less 
than half of peanut-allergic patients who avoid tree nuts are also 
likely to be tree nut allergic on the basis of the results of CRD 
testing for tree nuts. However, this study did not perform oral 
food challenge (OFC) with the tree nuts tested, so the clinical 
significance of these findings is yet to be determined21.
Risk factors for peanut and tree nut allergy 
development
Numerous risk factors for the development of peanut and tree 
nut allergy have been identified, including family history of 
peanut allergy22,23, personal history of egg allergy, and personal 
history of atopic dermatitis24, including filaggrin mutations25. 
More controversial associations include maternal ingestion of 
peanut during pregnancy and lactation26,27 and soy consump-
tion in infancy28,29. Family history of peanut allergy is a long- 
established risk factor for peanut allergy24; however, many 
studies identifying family history as a risk factor took place in 
the era before early introduction was widely recommended30. As 
such, delayed oral exposure to peanut may have contributed to 
increased peanut allergy risk in children whose family members 
had peanut allergy in some studies.
Whereas early oral exposure appears to protect against 
peanut allergy development, multiple lines of indirect evidence 
suggest that early cutaneous exposure to peanuts is sensitizing. 
Mice exposed to peanut extract through the cutaneous route 
were found to become sensitized in a T helper type 2 (Th2)- 
dependent manner18. In one questionnaire-based study investi-
gating 133 peanut allergy cases and 150 non-allergic controls, 
median weekly household peanut consumption (MWHP) was 
18.8 g in the peanut-allergic group compared with 6.9 g in the 
non-allergic controls31, suggesting that children in households 
in which more peanut products were consumed were at higher 
risk of developing peanut allergy, perhaps through cutaneous 
contact with peanut particles.
Though less exhaustively studied than those for peanut 
allergy, the risk factors for tree nut allergy are similar to those for 
peanut allergy. In one registry of 5,149 mostly pediatric patients 
with legume and tree nut allergy, 1,667 were found to be tree 
nut allergic32. Of these, walnut allergy was most common (34%), 
followed by cashew (20%), almond (15%), pecan (9%), and 
pistachio (7%)32. Allergies to hazelnut, pine nut, and macadamia 
occurred among less than 5% of the tree nut-allergic group.
Natural history of peanut and tree nut allergy in 
childhood
Experts have long considered peanut and tree nut allergy to 
be highly persistent. Owing in part to the severity of peanut 
allergy, providers have been hesitant to re-introduce pea-
nuts to patients with a history of peanut allergy. A 1989 study 
involving 32 subjects with food challenge-proven peanut allergy 
measured skin reactivity as its primary means of determining 
the persistence of peanut allergy and concluded that none of the 
study subjects had outgrown their allergy. However, newer data 
contradict this paradigm, indicating that as many as 21.5% of 
children with peanut allergy are able to tolerate peanuts at an 
increased age33. A subsequent study showed that in the subgroup 
of peanut-allergic children with initial peanut sIgE of not more 
than 5 kUA/L, more than half can be expected to outgrow their 
allergy34. Generally, higher SPT and peanut-specific sIgE 
appear to correlate with more-persistent allergy whereas lower 
values indicate allergy that is more likely to fade with time. One 
study found that SPT 6 mm or greater and peanut sIgE 3 kUA/L 
were each predictive of persistent peanut allergy35. Another found 
that low peanut sIgE and decreasing SPT size between the ages 
of 1 and 4 were crucial determinants that foretold remission or 
resolution of peanut allergy36. This study also found that when 
peanut allergy did resolve, it was most likely to occur before the 
age of 836.
There are fewer data on the natural history of tree nut allergy. 
One study involving 278 patients with tree nut allergy found that 
only 9% of the overall group outgrew their allergy. However, 
as with peanut allergies, sIgE appeared to correlate well with 
prognosis, as 63% of patients with sIgE to tree nuts less than 
2 kUA/L and 75% of patients with negative sIgE outgrew their 
allergy37.
Understanding the pathophysiology of nut allergy
Given the recent increase in the prevalence of nut allergy, there 
has been great interest in understanding the pathogenesis of this 
disease state. Numerous explanations have been offered for 
the global rise in nut allergy, but no single hypothesis offers a 
unifying theory of disease.
The hygiene hypothesis, which has its basis in the observa-
tion that Th2-mediated diseases like asthma and eczema are less 
common in developing countries, has been offered as an 
explanation for increased food allergy in developed countries38. 
In the absence of frequent infection, and exposure of the immune 
system to a variety of microbial antigens, there is dysregulation 
of Th1, Th2, and regulatory T (Treg) responses. The hygiene 
hypothesis, however, cannot fully account for the increasing 
burden of food allergy39.
Emerging research on the cutaneous and enteric microbi-
ome has led some researchers to argue that the term “hygiene 
hypothesis” is too narrow and that immune development is 
influenced not only by helminths but also by bacterial and viral 
organisms. Some prefer the term “biome depletion” for its 
more inclusive scope40. Specific commensal bacterial species 
(that is, Bacteroides and Lactobacillus) have been associated 
with decreased risk of atopic disease in animal models41, and the 
chemical metabolites produced by these organisms (particu-
larly short-chain fatty acids) have been associated with beneficial 
effects on allergy and atopy42.
Furthermore, the gut microbiome may play an important role in 
the development of peanut and tree nut allergy. In one study, mice 
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given antibiotics early in life were more likely to become 
sensitized to peanuts, and further experiments suggested that 
Clostridium species in particular were able to “shield” highly 
allergenic peanut proteins from the bloodstream43. These find-
ings have led to the hypothesis that increased antibiotic exposure 
may in part explain the recent rise in peanut allergy in children42.
Other hypotheses about the development of allergy have been 
cultivated on the basis of animal research and epidemiologic 
studies. There is some evidence to suggest a benefit associated 
with omega-3 and omega-6 fatty acid supplementation, although a 
recent Cochrane review showed no clear benefit of fatty 
acid supplementation during childhood in human studies44. 
Antioxidants may also protect against allergy development45.
Skin exposure to food allergens in early childhood is another 
intriguing hypothesis for the development of allergy. This 
hypothesis stems from the observation that antigens introduced 
to the skin of experimental animals are more likely to provoke 
an allergic response than antigens exposed to the oral mucosa or 
gastrointestinal tract. Peanut antigens, in particular, seem to be 
particularly effective at eliciting an allergic immune reaction in 
murine skin. Mice exposed to peanut extract or Ara h 2 on skin 
frequently develop a Th2 response18,46.
More research is needed to elucidate the pathogenesis of nut 
allergies and of food allergies generally. Overall, a Th2 response 
and immune dysregulation play an important role, a finding that 
has led to the “biome depletion” and the “hygiene hypothesis”.
The avoidance paradigm: journey to the American 
Academy of Pediatrics guidelines
In the 1990s, amidst a growing realization that food allergy 
was becoming more common worldwide, one study found that 
parents of patients with clinical peanut allergy were more likely 
to report the consumption of peanuts during pregnancy and early 
introduction of peanut products47. Despite the potential for recall 
bias in such lines of inquiry (that is, mothers whose children 
exhibited clinical peanut allergy may have been more likely 
to recall the consumption of peanuts), these findings were 
consistent with other results being published at the time. A large 
study from New Zealand found that early introduction of solid 
foods appeared to be correlated with eczema, which in turn was 
known to be associated with food allergy48. These and other 
lines of indirect evidence were considered in drafting the 1999 
European Society for Pediatric Allergology and Clinical Immu-
nology (ESPACI) and the European Society for Pediatric 
Gastroenterology, Hepatology, and Nutrition (ESPGHAN) 
guidelines for the prevention of food allergy. In 2000, the 
American Academy of Pediatrics (AAP) introduced parallel 
guidelines for the same purpose. High-risk infants were defined 
as those with a parent or sibling with food allergy. The 2000 
AAP guidelines recommended that mothers breastfeeding 
high-risk infants eliminate peanuts and tree nuts from their diet 
and that peanuts and tree nuts be avoided until 36 months of 
age. Notably, the latter recommendation was based on expert 
consensus rather than any clinical evidence; it was a significant 
departure from the ESPACI/ESPGHAN guidelines, which were 
far less restrictive and only recommended the avoidance of 
peanuts and tree nuts until 5 months of age. In its reasoning, the 
AAP reflected the contemporary thinking: that because peanut 
avoidance alone was unlikely to lead to nutritional deficiency, 
the potential benefit of peanut avoidance was likely to outweigh 
any disadvantages.
Paradigm shift: the LEAP, LEAP-On, and EAT studies
One crucial clue regarding the etiology of nut allergy came from 
the observation by British researchers in the mid-2000s that 
Ashkenazi Jewish children in the UK had far higher rates of 
peanut allergy than did Ashkenazi Jewish children in Israel49. 
Inquiry led to the insight that the UK children typically avoided 
peanut products in childhood but that the Israeli children 
were often given Bamba, a confection made from popped 
corn grits soaked in peanut butter, as an early solid food. In the 
Learning Early About Peanut Allergy (LEAP) study, Du Toit 
et al.50 selected infants at high risk for peanut allergy for 
inclusion in a single-site, prospective randomized design. 
During the initial screening, infants who had severe eczema or 
egg allergy were determined to be at high risk for developing 
peanut allergy and were selected for the trial50,51. SPT was 
performed, and 76 individuals with wheal size of more than 
4 mm were excluded from the trial50. Of the remaining 640 
participants, 530 were found to have a 0 mm wheal on SPT and 
98 had 1 to 4 mm wheals on SPT. Subjects were randomly 
assigned to peanut avoidance until age 5 or consumption of 6 g of 
peanut protein from enrollment until age 5. Even when baseline 
SPT results were accounted for, subjects randomly assigned to 
peanut consumption exhibited dramatically lower rates of clini-
cal peanut allergy by age 5 (2% versus 14% in the 0 mm wheal 
group and 10% versus 35% in the 1 to 4 mm group) (Table 1). 
In the LEAP-On study, participants from the LEAP study were 
instructed to avoid peanut consumption for 12 months. Twelve 
months of peanut avoidance did not significantly increase the 
rate of clinical peanut allergy in subjects who had been in the 
peanut consumption group during the LEAP study. At the 
conclusion of the LEAP-On study, the children who had been 
assigned to peanut consumption in the LEAP study had a 4.8% 
peanut allergy rate compared with an 18.6% peanut allergy 
rate in children who had been assigned to peanut avoidance. 
The findings of the LEAP-On study indicate that the benefit 
conferred by peanut product consumption in early life is 
lasting and durable, even if peanut consumption is paused later in 
childhood.
Table 1. Percentage of infants who developed 
clinical peanut allergy in a 5-year study 
window, stratified by wheal size ascertained 
before intervention.
0 mm wheal (n = 530) Consumption 1.9%
Avoidance 13.7%
1–4 mm wheal (n = 98) Consumption 10.3%
Avoidance 35.3%
Data are from the Learning Early About Peanut Allergy 
(LEAP) study. Adapted from Du Toit et al.51.
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The LEAP and LEAP-On studies involved only high-risk 
infants and peanuts. The Enquiring About Tolerance (EAT) 
study52, involving 1,303 infants in the UK, was a randomized 
prospective study designed to determine whether the early 
introduction of peanut, cooked egg, cow’s milk, sesame, 
whitefish, and wheat could reduce the occurrence of food 
allergy regardless of a priori allergy risk. This study, like LEAP, 
found a significant reduction in the incidence of peanut allergy 
with early introduction (2.4% with early introduction versus 
7.3% with standard introduction)52.
Implications for clinical practice: 2017 National Institute 
of Allergy and Infectious Diseases guidelines
In 2017, the National Institute of Allergy and Infectious 
Diseases (NIAID) released guidelines for the early introduction 
of peanut in selected children. These guidelines were heavily 
influenced by the findings of the LEAP study. The NIAID 
guidelines (summarized in Figure 1) constitute an algorith-
mic approach to early peanut introduction. The first step in this 
algorithm is risk-stratifying the patient. Infants with severe 
eczema or severe egg allergy or both are at highest risk of 
developing peanut allergy, and those in this “high-risk” group 
should undergo testing as soon as possible to determine 
whether they are already sensitized.
For “high-risk” infants, most practitioners should begin by 
ordering a peanut-specific IgE (sIgE). If this is less than 
0.35, which is most common, the risk of existing allergy is low 
and peanut products can be introduced at home or—for parents 
who are more concerned—in the office. For all “high-risk” 
infants, peanut introduction should occur as soon as possible, 
ideally at age 4 to 6 months. If the sIgE is at least 0.35, then 
SPT or allergy specialist referral is indicated. If SPT shows 0 to 
2 mm induration, then home introduction of peanut product is 
suitable. If SPT shows 3 to 7 mm induration, then supervised 
feeding in the office or a formal OFC is appropriate. Allergy 
specialist referral is warranted for infants who exhibit at least 
8 mm induration on SPT because these infants are likely to have 
clinical peanut allergy. Peanuts should not be given to infants 
with at least 8 mm SPT induration prior to specialist evaluation 
and management. Providers should keep in mind that, for high-
risk infants, the process of evaluation should begin as early as 
possible, as it can take some time for a SPT to be performed 
and peanuts should be introduced as early as 4 months in this 
group.
Most providers should begin with sIgE and consider SPT if 
sIgE is consistent with peanut sensitization. SPT is considered 
more precise by some. However, neither SPT nor sIgE alone can 
provide a definitive diagnosis; this requires clinical history that 
is consistent with food allergy or OFC. Infants with mild to 
moderate eczema but no severe egg allergy are considered to be 
at “intermediate risk” for peanut allergy. Unlike infants in the 
“high-risk” group, these infants do not need to undergo sIgE 
testing or SPT. They should be given peanut-containing foods 
at 6 months. No special evaluation or treatment is needed for 
infants who do not have eczema or food allergy. These infants 
constitute the “low-risk” group.
Figure 1. National Institute of Allergy and Infectious Diseases algorithm for risk stratification, evaluation, and management of infants 
with respect to peanut allergy. Adapted from Togias et al.53.
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In the LEAP study, Bamba (described earlier) was used and is a 
safe and suitable option for most infants, but peanut powders 
that can be mixed into applesauce or porridge are now commer-
cially available. A prepackaged mixture of applesauce and peanut 
(My Peanut™) is also commercially available. Smooth pea-
nut butter diluted with water or applesauce has also been used in 
some instances. Non-diluted peanut butter, whole peanuts, and 
crushed peanuts represent choking hazards and are not suitable 
for the early introduction of peanut.
Conclusions and future directions
Although our understanding of peanut allergy pathogenesis 
remains incomplete, the LEAP study and NIAID guidelines 
offer a clear departure from long-established practices. There are 
numerous challenges to the real-world implementation of 
these guidelines, most notably the problem of SPT or peanut- 
specific serum IgE testing, whose specificity and sensitivity in 
predicting clinical food allergy are suboptimal. Furthermore, 
access to allergy specialists, who are typically in great demand, 
may be a limiting factor for “high-risk” infants who require SPT 
prior to the initiation of peanut consumption at 4 to 6 months. 
The NIAID guidelines do not explicitly recommend a dose for 
early peanut consumption, but the original LEAP study used 
6 g of peanut protein per week, which translated to 21 Bamba 
sticks per week, split into three feedings of seven sticks. Another 
challenge is the issue of siblings with peanut allergies; siblings 
of a child with peanut allergy are at sevenfold increased risk of 
developing peanut allergy54. If an infant’s older sibling has 
peanut allergy, then regular feedings of peanut powder or 
Bamba sticks could be a source of anxiety for parents and 
caregivers. Such concerns are valid, and more public health and 
health systems research is needed to determine better ways to 
offer families timely, safe, and affordable access to evaluation 
and management for peanut allergy prevention. In the meantime, 
providers should take steps to offer early introduction of peanut 
where it is appropriate.
Abbreviations
AAP, American Academy of Pediatrics; CRD, component- 
resolved diagnostics; ESPACI, European Society for Pediatric 
Allergology and Clinical Immunology; ESPGHAN, Euro-
pean Society for Pediatric Gastroenterology, Hepatology, and 
Nutrition; LEAP, Learning Early About Peanut Allergy; NIAID, 
National Institute of Allergy and Infectious Diseases; OFC, 
oral food challenge; PRR, pattern recognition receptor; sIgE, 
specific IgE; SPT, skin prick test; Th, T helper
Grant information
The authors are supported by a grant from the National Institutes of 
Health (TL1TR001443). 
The funders had no role in study design, data collection and 
analysis, decision to publish, or preparation of the manuscript.
References F1000 recommended
1. Osborne NJ, Koplin JJ, Martin PE, et al.: Prevalence of challenge-proven IgE-
mediated food allergy using population-based sampling and predetermined 
challenge criteria in infants. J Allergy Clin Immunol. 2011; 127(3): 668–76.e1-2. 
PubMed Abstract | Publisher Full Text 
2. Gupta R, Holdford D, Bilaver L, et al.: The economic impact of childhood food 
allergy in the United States. JAMA Pediatr. 2013; 167(11): 1026–31.  
PubMed Abstract | Publisher Full Text 
3. Rudders SA, Arias SA, Camargo CA Jr: Trends in hospitalizations for food-
induced anaphylaxis in US children, 2000-2009. J Allergy Clin Immunol. 2014; 
134(4): 960–2.e3.  
PubMed Abstract | Publisher Full Text 
4. Bock SA, Muñoz-Furlong A, Sampson HA: Fatalities due to anaphylactic 
reactions to foods. J Allergy Clin Immunol. 2001; 107(1): 191–3.  
PubMed Abstract | Publisher Full Text 
5. Clark AT, Anagnostou K, Ewan PW: Cashew nut causes more severe reactions 
than peanut: case-matched comparison in 141 children. Allergy. 2007; 62(8): 
913–6.  
PubMed Abstract | Publisher Full Text 
6.  McWilliam V, Koplin J, Lodge C, et al.: The Prevalence of Tree Nut Allergy:  
A Systematic Review. Curr Allergy Asthma Rep. 2015; 15(9): 54.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
7.  Sicherer SH, Muñoz-Furlong A, Godbold JH, et al.: US prevalence of self-
reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin 
Immunol. 2010; 125(6): 1322–6.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
8.  Blom WM, Vlieg-Boerstra BJ, Kruizinga AG, et al.: Threshold dose 
distributions for 5 major allergenic foods in children. J Allergy Clin Immunol. 
2013; 131(1): 172–9.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
9. Waggoner MR: Parsing the peanut panic: the social life of a contested food 
allergy epidemic. Soc Sci Med. 2013; 90: 49–55.  
PubMed Abstract | Publisher Full Text | Free Full Text 
10. Primeau MN, Kagan R, Joseph L, et al.: The psychological burden of peanut 
allergy as perceived by adults with peanut allergy and the parents of peanut-
allergic children. Clin Exp Allergy. 2000; 30(8): 1135–43.  
PubMed Abstract | Publisher Full Text 
11. Avery NJ, King RM, Knight S, et al.: Assessment of quality of life in children with 
peanut allergy. Pediatr Allergy Immunol. 2003; 14(5): 378–82.  
PubMed Abstract | Publisher Full Text 
12. Bernard H, Paty E, Mondoulet L, et al.: Serological characteristics of peanut 
allergy in children. Allergy. 2003; 58(12): 1285–92.  
PubMed Abstract | Publisher Full Text 
13.  Yang L, Clements S, Joks R: A retrospective study of peanut and tree nut 
allergy: Sensitization and correlations with clinical manifestations. Allergy 
Rhinol (Providence). 2015; 6(1): 39–43.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
14. Barre A, Sordet C, Culerrier R, et al.: Vicilin allergens of peanut and tree nuts 
(walnut, hazelnut and cashew nut) share structurally related IgE-binding 
epitopes. Mol Immunol. 2008; 45(5): 1231–40.  
PubMed Abstract | Publisher Full Text 
15. Ntavli E, Turner PJ, Boyle RJ, et al.: Group 2 Innate Lymphoid Cells: New 
Players in Peanut Allergy. J Allergy Clin Immunol. 2016; 137(2): AB74.  
Publisher Full Text 
16. Khodoun M, Strait R, Orekov T, et al.: Peanuts can contribute to anaphylactic 
shock by activating complement. J Allergy Clin Immunol. 2009; 123(2): 342–51. 
PubMed Abstract | Publisher Full Text | Free Full Text 
17. van Wijk F, Nierkens S, Hassing I, et al.: The effect of the food matrix on  
in vivo immune responses to purified peanut allergens. Toxicol Sci. 2005; 86(2): 
333–41.  
PubMed Abstract | Publisher Full Text 
18.  Tordesillas L, Goswami R, Benedé S, et al.: Skin exposure promotes a 
Th2-dependent sensitization to peanut allergens. J Clin Invest. 2014; 124(11): 
4965–75.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
Page 7 of 9
F1000Research 2018, 7(F1000 Faculty Rev):1716 Last updated: 30 OCT 2018
19. Mittag D, Akkerdaas J, Ballmer-Weber BK, et al.: Ara h 8, a Bet v 1-homologous 
allergen from peanut, is a major allergen in patients with combined birch 
pollen and peanut allergy. J Allergy Clin Immunol. 2004; 114(6): 1410–7.  
PubMed Abstract | Publisher Full Text 
20. Baric̆ić TV, Dodig S: Genuine and Cross-Reactive Peanut Components in Birch-
Sensitive Preschool Children. Lab Med. 2013; 44(3): 210–4.  
Publisher Full Text 
21.  Uotila R, Kukkonen AK, Blom WM, et al.: Component-resolved diagnostics 
demonstrates that most peanut-allergic individuals could potentially introduce 
tree nuts to their diet. Clin Exp Allergy. 2018; 48(6): 712–21.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
22. Sicherer SH, Furlong TJ, Maes HH, et al.: Genetics of peanut allergy: a twin 
study. J Allergy Clin Immunol. 2000; 106(1 Pt 1): 53–6.  
PubMed Abstract | Publisher Full Text 
23. Tsai HJ, Kumar R, Pongracic J, et al.: Familial aggregation of food allergy and 
sensitization to food allergens: a family-based study. Clin Exp Allergy. 2009; 
39(1): 101–9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
24. Hourihane JO, Dean TP, Warner JO: Peanut allergy in relation to heredity, 
maternal diet, and other atopic diseases: results of a questionnaire survey, 
skin prick testing, and food challenges. BMJ. 1996; 313(7056): 518–21.  
PubMed Abstract | Publisher Full Text | Free Full Text 
25.  Brown SJ, Asai Y, Cordell HJ, et al.: Loss-of-function variants in the filaggrin 
gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol. 
2011; 127(3): 661–7.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
26.  Sicherer SH, Wood RA, Stablein D, et al.: Maternal consumption of peanut 
during pregnancy is associated with peanut sensitization in atopic infants.  
J Allergy Clin Immunol. 2010; 126(6): 1191–7.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
27. López-Expósito I, Song Y, Järvinen KM, et al.: Maternal peanut exposure during 
pregnancy and lactation reduces peanut allergy risk in offspring. J Allergy Clin 
Immunol. 2009; 124(5): 1039–46.  
PubMed Abstract | Publisher Full Text | Free Full Text 
28. Koplin J, Dharmage SC, Gurrin L, et al.: Soy consumption is not a risk factor for 
peanut sensitization. J Allergy Clin Immunol. 2008; 121(6): 1455–9.  
PubMed Abstract | Publisher Full Text 
29. Klemola T, Kalimo K, Poussa T, et al.: Feeding a soy formula to children with 
cow’s milk allergy: the development of immunoglobulin E-mediated allergy to 
soy and peanuts. Pediatr Allergy Immunol. 2005; 16(8): 641–6.  
PubMed Abstract | Publisher Full Text 
30. Lavine E, Clarke A, Joseph L, et al.: Peanut avoidance and peanut allergy 
diagnosis in siblings of peanut allergic children. Clin Exp Allergy. 2015; 45(1): 
249–54.  
PubMed Abstract | Publisher Full Text 
31. Fox AT, Sasieni P, du Toit G, et al.: Household peanut consumption as a risk 
factor for the development of peanut allergy. J Allergy Clin Immunol. 2009; 
123(2): 417–23.  
PubMed Abstract | Publisher Full Text 
32. Sicherer SH, Furlong TJ, Muñoz-Furlong A, et al.: A voluntary registry for peanut 
and tree nut allergy: characteristics of the first 5149 registrants. J Allergy Clin 
Immunol. 2001; 108(1): 128–32.  
PubMed Abstract | Publisher Full Text 
33. Skolnick HS, Conover-Walker MK, Koerner CB, et al.: The natural history of 
peanut allergy. J Allergy Clin Immunol. 2001; 107(2): 367–74.  
PubMed Abstract | Publisher Full Text 
34. Fleischer DM, Conover-Walker MK, Christie L, et al.: The natural progression 
of peanut allergy: Resolution and the possibility of recurrence. J Allergy Clin 
Immunol. 2003; 112(1): 183–9.  
PubMed Abstract | Publisher Full Text 
35. Ho MH, Wong WH, Heine RG, et al.: Early clinical predictors of remission of 
peanut allergy in children. J Allergy Clin Immunol. 2008; 121(3): 731–6.  
PubMed Abstract | Publisher Full Text 
36. Bégin P, Paradis L, Paradis J, et al.: Natural resolution of peanut allergy: a 
12-year longitudinal follow-up study. J Allergy Clin Immunol Pract. 2013; 1(5): 
528–30.e1-4.  
PubMed Abstract | Publisher Full Text 
37. Fleischer DM, Conover-Walker MK, Matsui EC, et al.: The natural history of tree 
nut allergy. J Allergy Clin Immunol. 2005; 116(5): 1087–93.  
PubMed Abstract | Publisher Full Text 
38. Yazdanbakhsh M, Kremsner PG, van Ree R: Allergy, parasites, and the hygiene 
hypothesis. Science. 2002; 296(5567): 490–4.  
PubMed Abstract | Publisher Full Text 
39. Prescott SL, Pawankar R, Allen KJ, et al.: A global survey of changing patterns 
of food allergy burden in children. World Allergy Organ J. 2013; 6(1): 21.  
PubMed Abstract | Publisher Full Text | Free Full Text 
40. Parker W: The “hygiene hypothesis” for allergic disease is a misnomer. BMJ. 
2014; 348: g5267.  
PubMed Abstract | Publisher Full Text 
41.  Panzer AR, Lynch SV: Influence and effect of the human microbiome in 
allergy and asthma. Curr Opin Rheumatol. 2015; 27(4): 373–80.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
42.  Blázquez AB, Berin MC: Microbiome and food allergy. Transl Res. 2017; 179: 
199–203.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
43.  Stefka AT, Feehley T, Tripathi P, et al.: Commensal bacteria protect against 
food allergen sensitization. Proc Natl Acad Sci U S A. 2014; 111(36): 13145–50. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
44. Anandan C, Nurmatov U, Sheikh A: Omega 3 and 6 oils for primary prevention 
of allergic disease: systematic review and meta-analysis. Allergy. 2009; 64(6): 
840–8.  
PubMed Abstract | Publisher Full Text 
45. Devereux G: The increase in the prevalence of asthma and allergy: food for 
thought. Nat Rev Immunol. 2006; 6(11): 869–74.  
PubMed Abstract | Publisher Full Text 
46.  Noti M, Kim BS, Siracusa MC, et al.: Exposure to food allergens through 
inflamed skin promotes intestinal food allergy through the thymic stromal 
lymphopoietin-basophil axis. J Allergy Clin Immunol. 2014; 133(5): 1390–9,  
1399.e1–6.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
47. Frank L, Marian A, Visser M, et al.: Exposure to peanuts in utero and in infancy 
and the development of sensitization to peanut allergens in young children. 
Pediatr Allergy Immunol. 1999; 10(1): 27–32.  
PubMed Abstract | Publisher Full Text 
48. Fergusson DM, Horwood LJ, Beautrais AL, et al.: Eczema and infant diet. Clin 
Allergy. 1981; 11(4): 325–31.  
PubMed Abstract | Publisher Full Text 
49.  Du Toit G, Katz Y, Sasieni P, et al.: Early consumption of peanuts in infancy 
is associated with a low prevalence of peanut allergy. J Allergy Clin Immunol. 
2008; 122(5): 984–91.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
50. Du Toit G, Roberts G, Sayre PH, et al.: Identifying infants at high risk of peanut 
allergy: the Learning Early About Peanut Allergy (LEAP) screening study. J 
Allergy Clin Immunol. 2013; 131(1): 135–43.e1-12.  
PubMed Abstract | Publisher Full Text 
51.  Du Toit G, Roberts G, Sayre PH, et al.: Randomized trial of peanut consumption 
in infants at risk for peanut allergy. N Engl J Med. 2015; 372(9): 803–13.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
52.  Perkin MR, Logan K, Tseng A, et al.: Randomized Trial of Introduction of 
Allergenic Foods in Breast-Fed Infants. N Engl J Med. 2016; 374(18): 1733–43. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
53. Togias A, Cooper SF, Acebal ML, et al.: Addendum guidelines for the prevention 
of peanut allergy in the United States: Report of the National Institute of 
Allergy and Infectious Diseases-sponsored expert panel. Allergy Asthma Clin 
Immunol. 2017; 13: 1.  
Publisher Full Text
54. Liem JJ, Huq S, Kozyrskyj AL, et al.: Should Younger Siblings of Peanut-Allergic 
Children Be Assessed by an Allergist before Being Fed Peanut? Allergy Asthma 
Clin Immunol. 2008; 4(4): 144–9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
Page 8 of 9
F1000Research 2018, 7(F1000 Faculty Rev):1716 Last updated: 30 OCT 2018
 Open Peer Review
  Current Referee Status:
Editorial Note on the Review Process
 are commissioned from members of the prestigious   and are edited as aF1000 Faculty Reviews F1000 Faculty
service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees
provide input before publication and only the final, revised version is published. The referees who approved the
final version are listed with their names and affiliations but without their reports on earlier versions (any comments
will already have been addressed in the published version).
The referees who approved this article are:
Version 1
The benefits of publishing with F1000Research:
Your article is published within days, with no editorial bias
You can publish traditional articles, null/negative results, case reports, data notes and more
The peer review process is transparent and collaborative
Your article is indexed in PubMed after passing peer review
Dedicated customer support at every stage
For pre-submission enquiries, contact   research@f1000.com
 Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA Cecilia Berin
 No competing interests were disclosed.Competing Interests:
1
 Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA;Jacqueline A. Pongracic
Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA 
 No competing interests were disclosed.Competing Interests:
2
Page 9 of 9
F1000Research 2018, 7(F1000 Faculty Rev):1716 Last updated: 30 OCT 2018
